Abstract
Cardiovascular diseases are still the main cause of morbidity and mortality in the world. Anti-platelet drugs have found clinical application in the secondary prevention of vascular events including acute myocardial infarction, stroke and cardiovascular death. In the present review, we have developed sixteen quantitative structure-activity relationships (QSAR) for different sets of compounds that are X-phenols (I), Xcatechols (II ), caffeic acid amides (III), X-alcohols (IV), 1,4-naphthoquinones (V), tetrahydronaphthalenes (VI), phenoxyacetaldehyde guanylhydrazones (VII), pyrrolobenzylisoquinolines (VIII) and phosphonic acids (IX) with respect to their anti-platelet activities. QSAR results have shown that the anti-platelet activities of these compounds are largely dependent not only on their hydrophobicity, but also on the influence of their molar refractivity.
Keywords: Platelet aggregation inhibitors, Hydrophobicity, CMR, QSAR, Adenosine diphosphate (ADP), Arachidonic acid (AA), collagen (Col), Thrombin (Thr)
Mini-Reviews in Medicinal Chemistry
Title: A Classical QSAR Study on Some Platelet Aggregation Inhibitors
Volume: 6 Issue: 4
Author(s): Rajeshwar P. Verma
Affiliation:
Keywords: Platelet aggregation inhibitors, Hydrophobicity, CMR, QSAR, Adenosine diphosphate (ADP), Arachidonic acid (AA), collagen (Col), Thrombin (Thr)
Abstract: Cardiovascular diseases are still the main cause of morbidity and mortality in the world. Anti-platelet drugs have found clinical application in the secondary prevention of vascular events including acute myocardial infarction, stroke and cardiovascular death. In the present review, we have developed sixteen quantitative structure-activity relationships (QSAR) for different sets of compounds that are X-phenols (I), Xcatechols (II ), caffeic acid amides (III), X-alcohols (IV), 1,4-naphthoquinones (V), tetrahydronaphthalenes (VI), phenoxyacetaldehyde guanylhydrazones (VII), pyrrolobenzylisoquinolines (VIII) and phosphonic acids (IX) with respect to their anti-platelet activities. QSAR results have shown that the anti-platelet activities of these compounds are largely dependent not only on their hydrophobicity, but also on the influence of their molar refractivity.
Export Options
About this article
Cite this article as:
Verma P. Rajeshwar, A Classical QSAR Study on Some Platelet Aggregation Inhibitors, Mini-Reviews in Medicinal Chemistry 2006; 6 (4) . https://dx.doi.org/10.2174/138955706776361484
DOI https://dx.doi.org/10.2174/138955706776361484 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
QSAR in the Pharmaceutical Research Setting: QSAR Models for Broad, Large Problems
Current Topics in Medicinal Chemistry Computational Study and Synthesis of a New Class of Anticonvulsants with 6 Hz Psychomotor Seizure Test Activity: 2-(1,3-benzodioxol-5-yloxy)- N'-[substituted]-acetohydrazides
Medicinal Chemistry Editorial: Statins or Fibrates for the Primary Prevention of Stroke in the Elderly. Faith Makes Some Things Achievable, But Not A
Current Vascular Pharmacology Meet Our Editorial Board Member
Cardiovascular & Hematological Agents in Medicinal Chemistry Augmentation Therapy with Alpha1-antitrypsin: Novel Perspectives
Cardiovascular & Hematological Disorders-Drug Targets A Survey on the Applications of Implantable Micropump Systems in Drug Delivery
Current Drug Delivery Editorial [Hot Topic: Nitric Oxide (Guest Editor: Greg Thatcher)]
Current Topics in Medicinal Chemistry Antiplatelet Treatment in Stroke: New Insights
Current Pharmaceutical Design Brain Slices as Models for Neurodegenerative Disease and Screening Platforms to Identify Novel Therapeutics
Current Neuropharmacology PF-04886847 (an Inhibitor of Plasma Kallikrein) Attenuates Inflammatory Mediators and Activation of Blood Coagulation in Rat Model of Lipopolysaccharide (LPS) - Induced Sepsis
Cardiovascular & Hematological Agents in Medicinal Chemistry Cerebral Aneurysm as an Exacerbating Factor in Stroke Pathology and a Therapeutic Target for Neuroprotection
Current Pharmaceutical Design Dry Age-Related Macular Degeneration: Recent Progress of Therapeutic approaches
Current Molecular Pharmacology Effectiveness of Psychoeducational Interventions for Improving Symptoms, Health-Related Quality of Life, and Psychological well Being in Patients with Stable Angina
Current Cardiology Reviews Cell Therapy for the Treatment of Chronic Ischemic Heart Disease
Current Pharmaceutical Design Prevalence of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Alzheimers Disease, and its Relationship with Cognitive Impairment
Current Alzheimer Research Clinical Characteristics of Behcet’s Disease in 453 Egyptian Patients Suffering from Uveitis with Gender Comparison
Current Rheumatology Reviews Proximate Composition and Mineral Content of Some Cameroonian Traditional Sauc es Prepared from Red Sorrel Leaves (H ibiscus sabdariffa L.)
Current Nutrition & Food Science Editorial: Oxidative Stress in Pathophysiological Conditions
Current Vascular Pharmacology Pleiotropic Effects of HDL: Towards New Therapeutic Areas for HDL-Targeted Interventions
Current Molecular Medicine Pathogenesis and Management of Intradialytic Hypertension
Current Hypertension Reviews